• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?

作者信息

Rosansky Steven J, Glassock Richard J

机构信息

Dorn Research Institute, WJBD VA Hospital, Columbia, South Carolina, USA.

Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

出版信息

Kidney Int. 2014 Apr;85(4):723-7. doi: 10.1038/ki.2013.506.

DOI:10.1038/ki.2013.506
PMID:24682115
Abstract
摘要

相似文献

1
Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?估算的肾小球滤过率（GFR）下降是否是肾脏保护药物试验合适的替代终点？
Kidney Int. 2014 Apr;85(4):723-7. doi: 10.1038/ki.2013.506.
2
GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.肾小球滤过率下降作为临床试验中肾功能衰竭的替代终点：来自 37 项随机试验的治疗效果的荟萃分析。
Am J Kidney Dis. 2014 Dec;64(6):848-59. doi: 10.1053/j.ajkd.2014.08.017. Epub 2014 Oct 16.
3
GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.肾小球滤过率下降作为 CKD 临床试验的终点：由美国国家肾脏基金会和美国食品药品监督管理局赞助的科学研讨会。
Am J Kidney Dis. 2014 Dec;64(6):821-35. doi: 10.1053/j.ajkd.2014.07.030. Epub 2014 Oct 16.
4
GFR decline as an alternative end point in clinical trials to prevent ESRD: are we increasing treatment uncertainty for the sake of feasibility?在预防终末期肾病的临床试验中，将肾小球滤过率下降作为替代终点：我们是为了可行性而增加治疗的不确定性吗？
Am J Kidney Dis. 2014 Dec;64(6):841-4. doi: 10.1053/j.ajkd.2014.10.002.
5
Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study.基于估算肾小球滤过率的替代时间至事件终点在慢性肾脏病中的效用和有效性：一项模拟研究。
Am J Kidney Dis. 2014 Dec;64(6):867-79. doi: 10.1053/j.ajkd.2014.08.019. Epub 2014 Oct 31.
6
Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.肾小球滤过率斜率作为临床试验中肾脏疾病进展替代终点的性能：统计模拟。
J Am Soc Nephrol. 2019 Sep;30(9):1756-1769. doi: 10.1681/ASN.2019010009. Epub 2019 Jul 10.
7
GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.肾小球滤过率下降与随后的既定肾脏结局风险：37 项随机对照试验的荟萃分析。
Am J Kidney Dis. 2014 Dec;64(6):860-6. doi: 10.1053/j.ajkd.2014.08.018. Epub 2014 Oct 16.
8
GFR decline as an end point for clinical trials in CKD: a view from Europe.肾小球滤过率下降作为慢性肾脏病临床试验的终点：欧洲视角
Am J Kidney Dis. 2014 Dec;64(6):838-40. doi: 10.1053/j.ajkd.2014.10.001.
9
Surrogate endpoints and renal protection: focus on microalbuminuria.替代终点与肾脏保护：聚焦微量白蛋白尿
Blood Press Suppl. 1997;2:52-7.
10
Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.慢性肾脏病临床评估指南：AMED药品和医疗器械监管科学研究
Clin Exp Nephrol. 2018 Dec;22(6):1446-1475. doi: 10.1007/s10157-018-1615-x.

引用本文的文献

1
Challenges in predictive modelling of chronic kidney disease: A narrative review.慢性肾脏病预测模型面临的挑战：一篇综述
World J Nephrol. 2024 Sep 25;13(3):97214. doi: 10.5527/wjn.v13.i3.97214.
2
Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials.估算肾小球滤过率斜率作为心血管试验的终点。
Curr Heart Fail Rep. 2024 Aug;21(4):407-416. doi: 10.1007/s11897-024-00668-8. Epub 2024 May 25.
3
Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in Northern Europe.
北欧一家医院糖尿病中心成年患者的慢性肾脏病负担及肾功能快速下降情况
BMJ Open Diabetes Res Care. 2021 Jun;9(1). doi: 10.1136/bmjdrc-2021-002125.
4
Association of Hematuria with Renal Progression and Survival in Patients Who Underwent Living Donor Liver Transplant.活体肝移植患者血尿与肾脏进展及生存的关联
J Clin Med. 2021 Sep 24;10(19):4345. doi: 10.3390/jcm10194345.
5
Effects of sarpogrelate on microvascular complications with type 2 diabetes.沙格雷酯对2型糖尿病微血管并发症的影响。
Int J Clin Pharm. 2019 Apr;41(2):563-573. doi: 10.1007/s11096-019-00794-7. Epub 2019 Mar 12.
6
Joint Modeling of Repeated Measures and Competing Failure Events In a Study of Chronic Kidney Disease.慢性肾脏病研究中重复测量与竞争失效事件的联合建模
Stat Biosci. 2017 Dec;9(2):504-524. doi: 10.1007/s12561-016-9186-4. Epub 2016 Dec 27.
7
Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study.西洛他唑和肾素-血管紧张素系统（RAS）阻滞剂对韩国患者肾脏疾病进展的影响：一项回顾性队列研究。
Int J Clin Pharm. 2018 Feb;40(1):160-168. doi: 10.1007/s11096-017-0578-4. Epub 2017 Dec 27.
8
Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease.在慢性肾脏病队列研究中使用纵向生物标志物对肾衰竭进行动态预测
Stat Biosci. 2017 Dec;9(2):357-378. doi: 10.1007/s12561-016-9183-7. Epub 2016 Nov 7.
9
Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.不同糖尿病模型中肾素编码腺相关病毒驱动的高血压导致的进行性肾脏疾病。
J Am Soc Nephrol. 2018 Feb;29(2):477-491. doi: 10.1681/ASN.2017040385. Epub 2017 Oct 23.
10
Role of Pulse Wave Velocity in Patients with Chronic Kidney Disease Stages 3-5 on Long-Term Follow-Up.脉搏波速度在3 - 5期慢性肾脏病患者长期随访中的作用
Pulse (Basel). 2014 May;2(1-4):1-10. doi: 10.1159/000365834. Epub 2014 Aug 14.